Moreover, we provide compelling evidence that miR‐30d, at least in part, contributes to the effect of sildenafil in treating PAH, and our findings of PDE5A as a direct target gene of miR‐30d may be used as a novel strategy to inhibit PDE5A. Here, PDE5A is linked to pulmonary arterial hypertension.